Skip to content
ppharmaranks
Menu
Class IIOngoing

Buprenorphine Hydrochloride recall

FDA recall D-0527-2026 · initiated Mar 13, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated May 20, 2026How we research

ENDO USA, Inc. recalled Buprenorphine Hydrochloride in Mar 2026 — an FDA Class II recall (D-0527-2026) because Crystallization; identified as Buprenorphine free base.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Crystallization; identified as Buprenorphine free base

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027

Quantity recalled: 34,293 vials

Details

Product
Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.
Recalling company
Endo Pharms
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
USA Nationwide
Initiated
Mar 13, 2026
FDA report date
May 20, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Buprenorphine Hydrochloride recalled?
ENDO USA, Inc. recalled Buprenorphine Hydrochloride in Mar 2026 — an FDA Class II recall (D-0527-2026) because Crystallization; identified as Buprenorphine free base. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Buprenorphine Hydrochloride recalled?
Per the FDA enforcement record, the reason for recall D-0527-2026 was: Crystallization; identified as Buprenorphine free base
Is a recalled Buprenorphine Hydrochloride dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Buprenorphine Hydrochloride are affected?
Distributed: USA Nationwide. The recall covers these lots — Lot #: 84132, Exp 02/28/2027; 87693, Exp 03/31/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0527-2026.

Source: openFDA Drug Enforcement record D-0527-2026

← All drug recalls